Unibrol USP 250 mg Tablets called for quarantine
- 2021-01-18 14:44:11
//
Liquid Preparations for Oral Use and Dosage Forms Complying with WHO International Pharmacopoeia/General Monograph
This
monograph does not apply to liquids intended for oromucosal administration (for
example, gargles and mouthwashes).
Definition
Liquid preparations for oral use are usually solutions, emulsions or
suspensions containing one or more active ingredients in a suitable vehicle;
they may in some cases consist simply of a liquid active ingredient used as
such.
Liquid preparations for oral use
are either supplied in the finished form or, with the exception of Oral
emulsions, may also be prepared just before issue for use by dissolving or
dispersing granules or powder in the vehicle stated on the label.
The vehicle for any liquid
preparation for oral use is chosen having regard to the nature of the active
ingredient(s) and to provide organoleptic characteristics appropriate to the
intended use of the preparation.
Liquid preparations for oral use
may contain suitable antimicrobial preservatives, antioxidants and other
excipients such as dispersing, suspending, thickening, emulsifying, buffering,
wetting, solubilizing, stabilizing, flavouring and sweetening agents and
authorized colouring matter.
Liquid preparations for oral use
may be supplied as multi-dose or as single-dose preparations. Each dose from a
multi-dose container is administered by means of a device suitable for
measuring the prescribed volume.
The device is usually a spoon or
a cup for volumes of 5 mL or multiples thereof, or an oral syringe for other
volumes or, for Oral drops, a suitable dropper.
Additional information
Liquid preparations for oral use
are often the dosage form of choice for paediatric use.
Owing to the wide range of liquid
preparations for oral use and their long history of use, a variety of terms has
been used to describe different members of this category of preparation. These
terms, which are not mutually exclusive and the definitions of which have
changed over time, include elixirs, linctuses, milks, mixtures and syrups.
Such terms are still used within
the titles of certain specific, long-established, traditional preparations (for
example, ephedrine elixir, codeine linctus, acid gentian mixture).
With such exceptions, however, it
is recommended that the titles of liquid dosage forms for oral use are based on
the terms used as sub-monograph headings in this general monograph.
The term syrup (denoting a
solution containing a high proportion of sucrose) is used, inter
alia, for certain solutions (for example, black currant syrup, lemon
syrup) that are used as vehicle ingredients for their sweetening and flavouring
properties.
Such syrups are not dosage forms
in the pharmacopoeial sense: they do not contain any active ingredient and are
not intended to be administered as such.
Oral solutions containing one or
more active ingredients dissolved in a vehicle containing a high proportion of
sucrose or a suitable polyhydric alcohol or alcohols and which may contain
ethanol have traditionally been called elixirs.
Viscous oral solutions containing
one or more active ingredients dissolved in a vehicle containing a high
proportion of sucrose, other sugars or a suitable polyhydric alcohol or
alcohols and which are intended for use in the treatment or relief of cough
have traditionally been called linctuses. They are intended to be sipped and
swallowed slowly without the addition of water.
Manufacture
The manufacturing process for
liquid preparations for oral use should meet the requirements of Good
Manufacturing Practice (GMP).
The following information is
intended to provide broad guidelines concerning the critical steps to be
followed during production of liquid preparations for oral use.
In the manufacture of liquid
preparations for oral use, measures are taken to:
ü
ensure that all
ingredients are of appropriate quality
ü
minimize the risk of
microbial contamination (see recommendations in chapter MICROBIOLOGICAL QUALITY OF NON-STERILE PRODUCTS: RECOMMENDED
ACCEPTANCE CRITERIA FOR PHARMACEUTICAL PREPARATIONS of the supplementary information section.);
ü
minimize the risk of
cross-contamination
During the development of a
preparation, the formulation for which contains one or more antimicrobial
preservatives, the effectiveness of the chosen preservative system shall be
demonstrated to the satisfaction of the relevant regulatory authority.
Appropriate measures should also
be taken to optimize the stability of the active ingredient(s) in liquid
formulations including those prepared from powder or granules.
Additional measures should be
taken so that, when stored under the conditions stated on the label, oral
solutions are not subject to precipitation and oral suspensions are not subject
to fast sedimentation, lump formation or caking.
During development of a
single-dose liquid preparation for oral use it shall be demonstrated that the
nominal content can be withdrawn from the container.
In the production of liquid
preparations for oral use containing dispersed particles, measures are taken to
ensure a suitable and controlled particle size and, where appropriate, crystal
structure (polymorphic and/or solvated forms) with regard to the intended use.
Throughout manufacturing, certain
procedures should be validated and monitored by carrying out appropriate
in-process controls. These should be designed to guarantee the effectiveness of
each stage of production. In-process controls during the manufacture of oral
liquids should include pH and fill volume. The validation of the manufacturing
process and the in-process controls are documented.
Safety concerns An important aspect of Good Manufacturing Practice for all pharmaceutical products is assuring the quality of all the starting materials used. The need for analytical testing to check the identity and quality of starting materials is explained in detail in section 14 of the current WHO GMP guidelines1. Failure to ensure that starting materials are of the required quality can have very serious consequences. Increasingly countries are dependent on the importation of starting materials for use in the production of medicines. Starting materials often change hands many times before reaching the manufacturer of the final marketed product and there are many opportunities for the material to undergo relabelling along the distribution and trade chain (see WHO Guideline on Good Trade and Distribution Practices for Pharmaceutical Starting Materials1). As a result, starting materials required for production of pharmaceutical products can become contaminated or materials may be supplied that no longer correspond to what is stated on the label in terms of quality or identity, either accidentally or as a result of negligence and sometimes fraud. The most documented incidents of contamination involve liquid preparations for oral use manufactured with excipients such as glycerol and propylene glycol that have been contaminated, adulterated or mixed up with diethylene glycol. Such incidents have been responsible for hundreds of deaths throughout the world (see, for example, editorial in WHO Bulletin 2001, 79(2)). Ingestion of diethylene glycol often leads to death through kidney failure. 1 For the current edition of WHO guidelines, please consult the WHO Medicines web site: http://www.who.int/medicines/en/. |
Uniformity of mass
Liquid preparations for oral use
that are presented as single-dose preparations comply with the following test.
Weigh individually the contents
of 20 containers, emptied as completely as possible, and determine the average
mass.
Not more than 2 of the individual
masses deviate by more than 10% from the average mass and none deviates by more
than 20%.
Uniformity of mass of
doses delivered by the measuring device
The measuring device provided
with a multi-dose liquid preparation for oral use complies with the following
test.
Weigh individually 20 doses taken
at random from one or more multi-dose containers with the measuring device
provided and determine the individual and average masses.
Not more than two of the
individual masses deviate by more than 10% from the average mass and none
deviates by more than 20%.
Containers
The containers should be made of material that will not adversely affect the
quality of the preparation by, for example, leaching or sorption.
Liquid preparations for oral use
that contain light-sensitive active ingredients are supplied in containers that
are light-resistant.
Except where indicated in the
individual monograph, containers should be made from material that is
sufficiently transparent to permit the visual inspection of the contents.
If the preparation contains volatile ingredients, the liquid preparation for oral use should be
kept in a tightly closed container.
Labelling
Every pharmaceutical preparation must comply with the labelling requirements
established under Good Manufacturing Practice.
The label should include:
1.
the name of the
pharmaceutical product;
2.
the name(s) of the
active ingredients; INNs should be used wherever possible;
3.
the amount of active
ingredient in a suitable dose-volume;
4.
the name and
concentration of any antimicrobial preservative and the name of any other
excipient;
5.
the batch (lot)
number assigned by the manufacturer;
6.
the expiry date and,
when required, the date of manufacture;
7.
any special storage
conditions or handling precautions that may be necessary;
8.
directions for use,
warnings, and precautions that may be necessary;
9.
the name and address
of the manufacturer or the person responsible for placing the product on the
market.
If the Liquid preparation for
oral use is supplied as granules or powder to be constituted just before issue
for use, the label should include:
1)
that the contents of
the container are granules or powder for the preparation of an oral liquid;
2)
the strength as the
amount of the active ingredient in a suitable dose-volume of the constituted
preparation;
3)
the directions for
preparing the oral liquid including the nature and quantity of liquid to be
used;
4)
the storage
conditions and shelf-life of the constituted preparation.
Requirements
for specific types of liquid preparations for oral use
Oral
solutions
Definition
Oral solutions are clear Liquid preparations for oral use containing one or
more active ingredients dissolved in a suitable vehicle.
Visual inspection
Inspect the solution. It should
be clear and free from any precipitate. A change in colour or cloudiness of
solutions may indicate chemical degradation or microbial contamination.
Oral
suspensions
Definition
Oral suspensions are Liquid preparations for oral use containing one or more
active ingredients suspended in a suitable vehicle. For oral suspensions
containing more than one active ingredient, some of the active ingredients may
be in solution.
Oral suspensions may show a
sediment which is readily dispersed on shaking to give a uniform suspension
which remains sufficiently stable to enable the correct dose to be delivered.
Visual inspection
Inspect the suspension. Evidence
of physical instability is demonstrated by the formation of flocculants or
sediments that do not readily disperse on gentle shaking. A change in colour
may indicate chemical degradation or microbial contamination.
Uniformity of content
For oral suspensions that are
presented as single-dose preparations and that contain less than 5 mg of active
ingredient per dose or in which the active ingredient is less than 5% of the
total weight per dose, carry out the following test. Shake and empty each
container as completely as possible and carry out the test as described
under 5.1
Uniformity of content for single-dose preparations. In such cases, the test
for Uniformity of mass prescribed above is not required.
Labelling
The label on the container should include a direction that the bottle should be
shaken before use.
Oral
emulsions
Definition
Oral emulsions are Liquid preparations for oral use containing one or more
active ingredients. They are stabilized oil-in-water dispersions,
either or both phases of which may contain dissolved solids. Solids may also be
suspended in Oral emulsions.
Oral emulsions may show evidence
of phase separation but are readily redispersed on shaking.
Visual inspection
Inspect the emulsion. Evidence of
physical instability is demonstrated by phase separation that is not readily
reversed on gentle shaking. A change in colour of emulsions may indicate
chemical degradation or microbial contamination.
Containers
When issued for use, Oral emulsions should be supplied in wide-mouthed bottles.
Labelling
The label on the container should include a direction that the bottle should be
shaken before use.
Oral
drops
Definition
Oral drops are Liquid preparations for oral use that are intended to be
administered in small volumes with the aid of a suitable measuring device. They
may be solutions, suspensions or emulsions.
Visual inspection
Inspect the drops. Drops that are
solutions should be clear and free from any precipitate. Evidence of physical
instability of drops that are suspensions is demonstrated by the formation of
flocculants or sediments that do not readily disperse on gentle shaking.
Evidence of physical instability of drops that
are emulsions is demonstrated by phase separation that is not readily reversed
on gentle shaking. A change in colour (or cloudiness of solutions) may indicate
chemical degradation or microbial contamination of the drops.
Dose and uniformity of
dose of oral drops
Into a suitable, graduated
cylinder, introduce by means of the dropping device the number of drops usually
prescribed for one dose or introduce by means of the measuring device the
usually prescribed quantity.
The dropping speed does not
exceed 2 drops per second. Weigh the liquid, repeat the addition, weigh again
and carry on repeating the addition and weighing until a total of 10 masses are
obtained.
No single mass deviates by more
than 10% from the average mass. The total of 10 masses does not differ by more
than 15% from the nominal mass of 10 doses. If appropriate, measure the total
volume of 10 doses. The volume does not differ by more than 15% from the
nominal volume of 10 doses.
Containers
Oral drops are normally supplied in suitable multi-dose containers that allow
successive drops of the preparation to be administered.
Powders
for oral solutions, oral suspensions or oral drops
Presentations of powder
(usually single-dose presentations, for example, a small sachet) that are
intended to be issued to the patient as a powder, to be taken in or with water
or another suitable liquid, are outside the scope of this general monograph.
Such preparations are controlled by the monograph for Oral powders.
Definition
Powders for oral solutions, suspensions or drops are multi-dose preparations
consisting of solid, loose, dry particles of varying degrees of fineness. They
contain one or more active ingredients, with or without excipients and, if
necessary, authorized colouring matter and flavouring substances.
They may contain antimicrobial
preservatives and other excipients in particular to facilitate dispersion or
dissolution and to prevent caking.
After dissolution or suspension
in the prescribed liquid, they comply with the requirements for Oral solutions,
Oral suspensions or Oral drops, as appropriate.
Manufacture
In the manufacture of powders for oral solutions, suspensions or drops, the
components of the powder mixture are passed through a sieve to remove lumps and
particle aggregates. The weighed masses of the sieved components, preferably of
a narrow particle size distribution, are then transferred to a suitable mixer.
The greatest risk of segregation
of the powder mixture usually occurs when emptying the mixer container and when
the powder mixture is dosed into the containers. Ensuring the suitability of
the mixing equipment and the dosing devices is, therefore, critical.
Visual inspection
Inspect the powder. Evidence of
physical instability is demonstrated by noticeable changes in physical
appearance, including texture (for example, clumping). A change in colour may
indicate chemical degradation or microbial contamination.
Granules for oral
solutions or suspensions
Presentations of granules
that are intended to be issued to the patient as granules to be swallowed as
such, to be chewed, or to be taken in or with water or another suitable liquid,
are outside the scope of this general monograph.
Definition
Granules for oral solutions or suspensions are multi-dose preparations
consisting of solid, dry aggregates of powder particles sufficiently resistant
to withstand handling. They contain one or more active ingredients with or
without excipients and, if necessary, authorized colouring matter and
flavouring substances.
They may contain antimicrobial
preservatives and other excipients in particular to facilitate dispersion or
dissolution and to prevent caking.
After dissolution or suspension
in the prescribed liquid, they comply with the requirements for Oral solutions
or Oral suspensions, as appropriate.
Visual inspection
Inspect the granules. Evidence of
physical instability is demonstrated by noticeable changes in physical
appearance, including texture (for example, clumping of granules, presence of
loose powder). A change in colour may indicate chemical degradation or microbial
contamination.
Reference
1. https://www.who.int/medicines/publications/pharmacopoeia/other_meds/en/
2. World
Health Organization WHO (2019). International Pharmacopoeia Ninth Edition by WHO Department of Essential Medicines and Health
Products